Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 345.56M P/E - EPS this Y 13.60% Ern Qtrly Grth -
Income -77.09M Forward P/E -3.85 EPS next Y 7.90% 50D Avg Chg -12.00%
Sales 10.06M PEG - EPS past 5Y - 200D Avg Chg -20.00%
Dividend N/A Price/Book 2.39 EPS next 5Y - 52W High Chg -34.00%
Recommedations 2.00 Quick Ratio 6.38 Shares Outstanding 188.78M 52W Low Chg 12.00%
Insider Own 22.30% ROA -30.59% Shares Float 135.51M Beta 1.91
Inst Own 51.52% ROE -59.96% Shares Shorted/Prior 6.56M/6.64M Price 2.08
Gross Margin - Profit Margin - Avg. Volume 566,532 Target Price 5.00
Oper. Margin -1,238.24% Earnings Date Nov 5 Volume 483,415 Change -4.59%
About Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Arbutus Biopharma Corporation News
11/15/24 Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
11/15/24 Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
11/14/24 Arbutus to Present at Jefferies London Healthcare Conference
11/07/24 Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ...
11/07/24 Q3 2024 Arbutus Biopharma Corp Earnings Call
11/06/24 Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
11/06/24 Arbutus: Q3 Earnings Snapshot
11/06/24 Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
10/23/24 Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
10/15/24 Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
10/01/24 Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
09/25/24 Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year?
09/09/24 Are Medical Stocks Lagging HCA Healthcare (HCA) This Year?
09/03/24 Arbutus to Participate in Two Upcoming Investor Conferences
08/22/24 Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
08/06/24 Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
08/02/24 Q2 2024 Arbutus Biopharma Corp Earnings Call
08/01/24 Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates
08/01/24 Arbutus: Q2 Earnings Snapshot
08/01/24 Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
ABUS Chatroom

User Image rookiehoosier Posted - 45 minutes from now

$ABUS thought presentation went well but feel much less confident that there is any pending news. Had been very hopeful this was ride off into the sunset year for Sofia but feels like into 2025 before any chance of a partnership/buyout happening

User Image bs010101 Posted - 8 minutes from now

$ABUS presentation started; Dennis Ding from Jefferies is host

User Image bs010101 Posted - 5 minutes from now

$ABUS

User Image PenkeTrading Posted - 4 hours ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Arbutus Biopharma Corp. Is that bullish or bearish? $ABUS #RsiOversold #NASDAQ

User Image DDRPOWER Posted - 12 hours ago

$ABUS They say good things don’t come easy..

User Image C_Bass Posted - 13 hours ago

$ABUS CEO/President & CFO at conference tomorrow? rather than CSO and/or CMO. Peaking my interest here…

User Image Shortsales Posted - 13 hours ago

$ABUS Bullish!

User Image brs555 Posted - 13 hours ago

$ABUS Keep milking it....

User Image C_Bass Posted - 13 hours ago

$ABUS and again, there’s your 9cent AH pop. How nice to catch that daily 😏

User Image bs010101 Posted - 14 hours ago

$ABUS

User Image tip2base Posted - 16 hours ago

$ABUS https://endpts.com/what-is-the-future-of-the-trump-admins-pharmaceutical-policies/

User Image Thepatientone Posted - 16 hours ago

$ABUS - Buy buy buy... ABUS long and strong.

User Image C_Bass Posted - 16 hours ago

@___dog___ @mickeyp_ they’re going to need that $8B cash to pay $ABUS. I’m shocked more people aren’t moving their money to the rightful owner of the stolen intellectual property

User Image SpaceCityKid Posted - 16 hours ago

$ABUS Still holding above hammer low and the 200 day. Also, RSI < 30, so oversold. But still no vol volume which would confirm a bottom.

User Image anthonydabbraccio Posted - 17 hours ago

$ABUS we started climbing a year ago today. Let's see it repeat the process please.

User Image DocPharm Posted - 19 hours ago

$ABUS small adds (<500 shares/order) till my limits hit Looks like forming some support, but could be a facade so the limits stay

User Image IN0V8 Posted - 20 hours ago

$ABUS Watch / Oppoertunity Chardan Capital Markets raises PT to $5 from $4.5

User Image Joe_Mama Posted - 20 hours ago

$ABUS RSI approaching over sold. Bounce soon

User Image SpaceCityKid Posted - 20 hours ago

$ABUS Double bottom holds even with ugly mkt. Rally phase about to start

User Image C_Bass Posted - 20 hours ago

$ABUS the manipulation on this ticker is obnoxious. Still long.

User Image ShareholderIncentives Posted - 22 hours ago

$ABUS as expected, analyst coverage updates coming. JMP and Chardan are already out with their updates. Looking forward to Dennis Ding’s update, which should be within a few days.

User Image Heavey Posted - 23 hours ago

$ABUS

User Image anachartanalyst Posted - 1 day ago

$ABUS https://anachart.com/wp-content/uploads/ana_temp/1732100486_soc-img.jpg

User Image C_Bass Posted - 1 day ago

@forsiz1 they’re going to have to pay half their MC in royalties to $abus

User Image Heavey Posted - 1 day ago

$ABUS to tap into the Jefferies London Healthcare chat on Nov 21, link- https://wsw.com/webcast/jeff315/register.aspx?conf=jeff315&page=abus&url=https://wsw.com/webcast/jeff315/abus/1843548

User Image GABIRODZ01 Posted - 1 day ago

$ABUS

User Image brs555 Posted - 1 day ago

$ABUS Its now or never. Chart looks ready.

User Image bs010101 Posted - 1 day ago

$ABUS strange no analyst coverage/targets updates post-AASLD..

User Image MrVenndram Posted - 1 day ago

$ABUS People have mentioned before...Biontech... Embraces lnp sp and Sentiment rising Outside grasp RFK Jr Help out their "buddy" Pfizer What ya think?

User Image SpaceCityKid Posted - 1 day ago

$ABUS To me, the chart looks like we are in an a-b-c correction within a LT uptrend. A rally to the top of the falling channel @ 3.96-3.99 should begin soon. Then things get serious. Can it breakout or not.

Analyst Ratings
Jefferies Buy Sep 5, 24
JMP Securities Market Outperform Aug 2, 24
HC Wainwright & Co. Buy Jun 7, 24
HC Wainwright & Co. Buy Jun 6, 24
Chardan Capital Buy Jun 5, 24
Chardan Capital Buy May 3, 24
JMP Securities Market Outperform Apr 4, 24
Chardan Capital Buy Mar 1, 24
HC Wainwright & Co. Buy Mar 1, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Sims Karen Chief Medical Office.. Chief Medical Officer Feb 01 Sell 2.31 4,358 10,067 125,542 02/05/24
HASTINGS DAVID C Chief Financial Offi.. Chief Financial Officer Feb 01 Sell 2.31 9,593 22,160 181,907 02/05/24
Sofia Michael J. Chief Scientific Off.. Chief Scientific Officer Feb 01 Sell 2.31 9,982 23,058 1,485,121 02/05/24
McElhaugh Michael J. Interim President &.. Interim President & CEO Feb 01 Sell 2.31 10,164 23,479 1,504,793 02/05/24
McElhaugh Michael J. Chief Business Offic.. Chief Business Officer Dec 16 Sell 5 40,000 200,000 1,327,457 12/16/20